Al­ler­gan’s Botox miss­es the bulls­eye in PhII de­pres­sion study, but re­searchers con­fi­dent they can hit it in a ma­jor PhI­II

Al­ler­gan’s siz­able Phase II study test­ing Botox as a treat­ment for ma­jor de­pres­sion among women missed hit­ting sta­tis­ti­cal sig­nif­i­cance for the pri­ma­ry end­point at six weeks of ther­a­py. But it didn’t miss by much, and the low dose did score at a cou­ple of oth­er time points in the study, giv­ing Al­ler­gan $AGN ex­ecs enough con­fi­dence to move the ther­a­py in­to a ma­jor Phase III pro­gram.

Re­searchers put two dos­es of Botox — 30 units and 50 units — in­to the study, which re­cruit­ed 258 pa­tients. The 50-unit dose was a bust. But:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.